Trial Profile

IBCSG 25-02: A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer (TEXT)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 31 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Exemestane (Primary) ; Triptorelin (Primary) ; Tamoxifen
Indications Ductal carcinoma; Early breast cancer; HER2 negative breast cancer
Focus Therapeutic Use
Acronyms TEXT

26 Mar 2025 Status changed from active, no longer recruiting to completed.
15 Dec 2022 Results (n=4690) assessing the 12-year SOFT-TEXT late treatment effects on distant recurrence-free interval and overall survival and benefits in women with human epidermal growth factor receptor 2 negative tumors and in those at high risk of disease relapse, published in the Journal of Clinical Oncology.
12 Feb 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com